Plant dipeptidyl peptidase-IV inhibitors as antidiabetic agents: a brief review.

Abstract

Diabetes mellitus is an increasing public health problem in the world. Type 2 diabetes is the most common type of diabetes whose complications contribute to its high death rate. It seriously impacts healthcare systems and patients' quality of life. Therefore, effective measures and new treatment strategies are needed to solve this increasingly serious global problem. In recent years, inhibition of dipeptidyl peptidase IV (DPP-IV) has emerged as a new treatment option for Type 2 diabetes. This article reviews various plant DPP-IV inhibitors that showed inhibition toward enzyme as a major target for the management of Type 2 diabetes. These studies can contribute to the future development of DPP-IV inhibitors as drugs.

• Authors: Gulmira Turdu, Hongwei Gao, Yingying Jiang, Madina Kabas
• Journal: Future medicinal chemistry (Future Med Chem) Vol. 10 Issue 10 Pg. 1229-1239 (05 01 2018) ISSN: 1756-8927 [Electronic] England
• PMID: 29749760 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Biological Products
• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Dipeptidyl Peptidase 4

Topics

• Anacardiaceae (chemistry, metabolism)
• Biological Products (chemistry, isolation & purification, pharmacology)
• Diabetes Mellitus, Type 2 (drug therapy, pathology)
• Dipeptidyl Peptidase 4 (chemistry, metabolism)
• Dipeptidyl-Peptidase IV Inhibitors (chemistry, isolation & purification, therapeutic use)
• Humans
• Hypoglycemic Agents (chemistry, isolation & purification, therapeutic use)
• Rhizophoraceae (chemistry, metabolism)
• Smilax (chemistry, metabolism)
• Vigna (chemistry, metabolism)